|
|
|
|
|
|
|
|
|
|
|
08.10.26 - 12:06
|
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer (Business Wire)
|
|
|
Medical Technology Executive Brings More than 20 years of Leadership Experience, Including Cardiovascular, Endovascular and Oncology Markets, with a Track Record of Accelerating Growth and Improving Profitability
Jim Clemmer to Retire Following Ten Years as President and Chief Executive OfficerLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Eric Honroth as President and Chief Executive Officer and a member of the Board of Directors, effective November 2, 2026. Mr. Honroth will succeed Jim Clemmer, who will depart the Board on November 2, 2026, and will remain in a consulting capacity to ensure a smooth transition.
The appointment follows a Board-led search prioritizing a leader with medical technology experience, a demonstrated track record of comm...
|
|
|
08.10.26 - 12:06
|
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability (Business Wire)
|
|
|
Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDALATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2027, which ended August 31, 2026.
Fiscal Year 2027 First Quarter Financial Highlights
Quarter Ended
August 31, 2026
YoY Growth
Net Sales
$80.9 million
6.9%
Med Tech Net Sales
$39.9 million
13.2%
Med Device Net Sales
$41.0 million
1.4%
GAAP gross margin of 59.4%
GAAP loss per share of $0.17
Adjusted loss per share of $0.04
Adjusted EBITDA of $5.0 million
Announced the appointment of Eric Honroth as President and Chief Executive Officer, effective November 2, 2026, succeeding Jim Clemmer
Received FDA IDE (Investigational Device Exemption) approval for the R...
|
|
|
|
|
28.09.26 - 22:36
|
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 (Business Wire)
|
|
|
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results.
To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A recording of the call will also be available, until Thursday, October 15, 2026, 2026 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (dome...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.07.26 - 12:06
|
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability (Business Wire)
|
|
|
Delivered its seventh consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDALATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2026, which ended May 31, 2026.
Fiscal Year 2026 Fourth Quarter Financial Highlights
Quarter Ended
May 31, 2026
Pro Forma* YoY Growth
Pro Forma* Net Sales
$86.6 million
8.0%
Med Tech Net Sales
$41.8 million
16.7%
Med Device Net Sales
$44.8 million
1.1%
GAAP gross margin of 54.0%
GAAP loss per share of $0.27
Adjusted loss per share of $0.07
Adjusted EBITDA of $3.3 million
Fiscal Year 2026 Financial Highlights
Year Ended
May 31, 2026
Pro Forma* YoY Growth
Pro Forma* Net Sales
$320.2 million
9.4%
Med Tech Net Sales
$150.0 million...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
